REGENERON PHARMACEUTICALS, INC. (REGN) — SEC Filings

Latest SEC filings for REGENERON PHARMACEUTICALS, INC. (REGN), explained in plain English.

Sentiment Overview: 28 neutral, 1 mixed

Recent Filings (29)

• 13F-HR Filing — 13F-HR · 2025-11-07T00:00:00.000Z [neutral]
• Regeneron's Collaboration Gains Offset EYLEA Sales Dip, Net Income Rises — 10-Q · 2025-10-28T00:00:00.000Z [mixed] Risk: medium
  Regeneron Pharmaceuticals, Inc. reported a mixed financial performance for the nine months ended September 30, 2025. Net product sales decreased by 17.6% to $4.
• Regeneron Pharmaceuticals Files 8-K on Financials — 8-K · 2025-10-06T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed an 8-K on October 6, 2025, to report on its results of operations and financial condition. The filing does not contain spe
• 13F-HR Filing — 13F-HR · 2025-08-01T00:00:00.000Z [neutral]
• Regeneron Posts Modest Q2 Revenue Growth Amidst Steady Product Sales — 10-Q · 2025-08-01T00:00:00.000Z [neutral] Risk: medium
  REGENERON PHARMACEUTICALS, INC. reported total revenue of $3.15 billion for the second quarter of 2025, a slight increase from $3.08 billion in the prior-year q
• Regeneron Pharmaceuticals Reports on Shareholder Vote Matters — 8-K · 2025-06-18T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders on June 13, 2025. The filing details
• 13F-HR Filing — 13F-HR · 2025-05-02T00:00:00.000Z [neutral]
• Regeneron Files Q1 2025 10-Q — 10-Q · 2025-04-29T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the fi
• Regeneron Files 2025 Proxy Statement on Executive Compensation — DEF 14A · 2025-04-29T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed its Definitive Proxy Statement (DEF 14A) on April 29, 2025, for the fiscal year ending December 31, 2024. The filing detai
• 13F-HR Filing — 13F-HR · 2025-02-07T00:00:00.000Z [neutral]
• Regeneron Pharmaceuticals Files 2024 10-K — 10-K · 2025-02-05T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed its 2024 10-K on February 5, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered at 77
• Regeneron Pharmaceuticals Files 8-K — 8-K · 2025-02-04T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed an 8-K on February 4, 2025, reporting on results of operations, other events, and financial statements. The filing does no
• 8-K Filing — 8-K · 2025-01-13T00:00:00.000Z [neutral]
• Regeneron Pharmaceuticals Q3 2024 Update — 10-Q · 2024-10-31T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported significant product sales and collaboration revenu
• Regeneron Pharmaceuticals Files 8-K on Financials — 8-K · 2024-10-07T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed an 8-K on October 7, 2024, to report on its results of operations and financial condition. The filing does not contain spe
• Regeneron Files Q2 2024 10-Q — 10-Q · 2024-08-01T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the sec
• Regeneron Pharmaceuticals Files 8-K — 8-K · 2024-07-08T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed an 8-K on July 8, 2024, to report results of operations and financial condition. The filing does not contain specific fina
• Regeneron Pharmaceuticals Files 8-K on Security Holder Votes — 8-K · 2024-06-20T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed an 8-K on June 20, 2024, reporting on matters submitted to a vote of security holders on June 14, 2024. The filing details
• Regeneron Q1 2024 10-Q Filed — 10-Q · 2024-05-02T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported financial results for the first quarter of 2024, detai
• Regeneron Pharma Files 2023 DEF 14A on Executive Pay — DEF 14A · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  Regeneron Pharmaceuticals, Inc. filed its DEF 14A on April 25, 2024, for the fiscal year ending December 31, 2023. The filing details executive compensation, in
• Vanguard Amends Regeneron Stake: Holds 7.6% as of Dec 29, 2023 — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  The Vanguard Group, a major investment firm, filed an amendment to its Schedule 13G on February 13, 2024, disclosing its ownership in Regeneron Pharmaceuticals
• Capital World Investors Trims Regeneron Stake to 4.7% — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  Capital World Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, disclosing a slight decrease in its beneficial ownership
• FMR LLC Reports 9.63% Stake in Regeneron Pharma — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Regeneron Pharmaceuticals Inc. As of Decemb
• Regeneron 2023 10-K Filed: Financials Revealed — 10-K · 2024-02-05T00:00:00.000Z [neutral]
  Regeneron Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 31, 2023, on February 5, 2024. The filing provides a comprehensive overview o
• Regeneron Files 8-K on Financial Results & Operations — 8-K · 2024-02-02T00:00:00.000Z [neutral]
  Regeneron Pharmaceuticals, Inc. filed an 8-K on February 2, 2024, to report on its results of operations and financial condition. This filing indicates that the
• Regeneron 8-K: Executive Comp/Officer Changes Reported Jan 26 — 8-K · 2024-01-31T00:00:00.000Z [neutral]
  Regeneron Pharmaceuticals, Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 26, 2024. This filing is categorized under 'Depart
• BlackRock Amends Regeneron Stake; Passive Investment Update — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended Schedule 13G/A on January 25, 2024, indicating a change in its ownership of Regeneron Pharmaceuticals Inc. common stock as of De
• JPMorgan Amends Regeneron Stake; Passive Ownership Update — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  JPMorgan Chase & Co. filed an amended Schedule 13G/A on January 25, 2024, indicating a change in its beneficial ownership of Regeneron Pharmaceuticals, Inc. com
• Regeneron Files 8-K on Results, Reg FD Disclosure — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Regeneron Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose information under Items 2.02 (Results of Operations and Financial Condition), 7.01